Cases That Test Your Skills

The painful truth about depression

Author and Disclosure Information

Eight weeks after remission, Ms. F’s depressive symptoms resurface. She’s tired, sleep-deprived, and has trouble functioning at work. Did a recent automobile accident contribute to her mood reversal?


 

References

History: Initial symptoms

Ms. F, age 39, presented with depression, severe anxiety, and disturbed sleep. She denied psychiatric or medical history, but reported that her depressive symptoms hampered her performance at work and led to work-related stress.

Ms. F’s Beck Depression Inventory (BDI) score at baseline was 21, indicating moderate depression. The psychiatrist diagnosed her as having generalized anxiety disorder and adjustment disorder with depressed mood.

The patient was started on paroxetine, 10 mg/d. Five weeks later, her anxiety had decreased significantly and her BDI score had dropped to 10, indicating normal mood. Both the patient and clinician decided at this point that Ms. F had reached remission. The patient demanded that paroxetine be stopped, saying that she “does not like medication.” The psychiatrist reluctantly agreed.

Eight weeks later, during a follow-up examination, Ms. F complained of severely depressed mood with frequent crying spells. She complained of fatigue, nausea, headaches, decreased appetite, and dizziness. Her work performance, which had improved during the paroxetine trial, was again compromised. Her BDI score was 32, indicating severe depression.

Was the psychiatrist justified in stopping paroxetine therapy after 5 weeks?

Dr. Fishbain’s observations

Premature paroxetine discontinuation cannot be ruled out as a cause for Ms. F’s relapse. Sood et al1 found that duration of antidepressant therapy beyond treatment guidelines correlated with longer times to relapse.

By contrast, Ms. F’s initial therapy duration fell short of the 6 to 8 weeks recommended by the American Psychiatric Association.2

Patients commonly cite adverse events as a reason for wanting to stop antidepressant therapy.3 Ms. F reported no adverse effects, however; she said only that she did “not like medication.” Despite her insistence to the contrary, antidepressant therapy probably should not have been stopped.

Further history: A painful discovery

After questioning, Ms. F told the psychiatrist that she had been involved in a motor vehicle accident 2 weeks before the follow-up visit and had since been suffering lower back and neck pain.

After more questioning, Mr. F revealed that the pain was disrupting her sleep. She was getting about 4 hours of fragmented sleep per night, resulting in lack of energy during the day. The pain made it hard for her to sit, further impairing her work performance.

Ms. F was restarted on paroxetine, 10 mg/d titrated across 6 weeks to 60 mg/d for her depression, and zolpidem, 10 mg at bedtime, to help her sleep. After 6 weeks, her BDI score improved to 20, and she was less labile. Her depressive symptoms persisted, however, as did her pain, fatigue, headaches, nausea, dizziness, and sleep disturbances.

What role did Ms. F’s pain play in her relapse? How can clinicians detect somatic symptoms and gauge their effect on mood?

Dr. Fishbain’s observations

Pain most likely caused Ms. F’s depression relapse. McBeth et al4 have demonstrated that pain can contribute to depression’s development. In another study,5 43.4% of subjects who met criteria for major depression reported painful symptoms. The presence of a chronic painful condition was also found to contribute to major depression.5

Nakao et al6 screened 2,215 outpatients who were referred with mind/body complaints. Patients who were diagnosed with major depression had significantly higher rates of fatigue (86% vs. 65%), insomnia (79% vs. 58%), nausea/vomiting (51% vs. 40%), and low-back pain (36% vs. 24%) than those who were not. Within the major depression group, somatic symptoms were more abundant in patients with severe depressive episodes than in those with mild depressive episodes (5.8 vs. 3.7, P < 0.05).

Depression prevalence appears to increase when somatic symptoms are considered in the diagnosis. Posse and Hallstrom7 used a two-stage design to screen for depression. In the first stage, depression prevalence was 1.8%. In the second stage, 62 patients with high somatic complaint scores were re-evaluated. Of this group, 41 were diagnosed with a major depressive disorder or dysthymia.

Patients with continued pain after depression treatment are at high risk for depression recurrence.8 Diffuseness of pain and extent to which it interferes with daily activities strongly predict depression.9

Diagnostic challenges. Patients with depression often present to their primary care physicians with somatic rather than behavioral symptoms, making it hard for the family doctor to diagnose depression.10 By contrast, when presenting to a psychiatrist, depressed patients tend to discuss their emotional symptoms but not their physical complaints.11 This is because patients often:

  • attribute physical symptoms to an unrelated medical illness
  • consider aches and pains a normal part of aging
  • or are not aware that psychiatrists can treat physical symptoms.11

Psychiatrists in the past have emphasized emotional symptoms while barely addressing physical symptoms. This trend is changing, however, as the link between physical pain and depression has become clearer.

Pages

Recommended Reading

Treatment-resistant depression: Is there any other kind?
MDedge Psychiatry
COPD: How to manage comorbid depression and anxiety
MDedge Psychiatry
Depressed patients won’t exercise? 7 ways to get them started
MDedge Psychiatry
Christmas depression: The data may surprise you
MDedge Psychiatry
Omega-3 fatty acids: Do ‘fish oils’ have a therapeutic role in psychiatry?
MDedge Psychiatry
Psychotic depression: State-of-the-art algorithm improves odds for remission
MDedge Psychiatry
Revised ‘SAD PERSONS’ helps assess suicide risk
MDedge Psychiatry
Treatment-resistant depression: Switch or augment? Choices that improve response rates
MDedge Psychiatry
SSRIs in children and adolescents: Where do we stand?
MDedge Psychiatry
Brain/body connection: Treating depression in patients with cardiovascular disease
MDedge Psychiatry